Conduct longitudinal studies to assess the long-term effects of PT alterations on HF progression.Elucidate the role of IGF-1 signalling and other pathways in mediating PT hypertrophy induced by loop diuretic therapy.Conduct clinical trials to identify predictors of optimal response to SGLT2 inhibitors in HF patients. This evidence concerns the gene SLC5A2 and hydrops fetalis.